Rovi Prioritizes Risperidone Filing In Europe Over US
Executive Summary
Spain’s Rovi is prioritizing European filing and filling preparations for its long-acting risperidone injectable, pushing back a prospective US regulatory submission until next year.
You may also be interested in...
Rovi Is Weeks From Long-Acting Risperidone Filing
Rovi hopes by the end of this year to file a hybrid marketing authorization application in Europe for a once-a-month sustained-release injectable formulation of risperidone. A US filing is scheduled for the first half of next year.
Rovi Rolls Out Enoxaparin In Portugal As It Prepares For Teriparatide
Rovi has started to market its enoxaparin biosimilar directly in Portugal as the Spanish company prepares to market teriparatide in its domestic market through a tie-up with Teva.
Pressure Mounts For German Tender Reforms
Germany’s off-patent industry association, Pro Generika, is finding ample support for its position that by awarding tender contracts to exclusive suppliers, health insurance funds are contributing to drug shortages in the country.